We observed that GOT2 expression was highest in patients harboring the C5 subtype (immunologically quiet) and lowest in patients exhibiting the C2 subtype (IFN-gamma dominant), indicating that GOT2 can be used as a marker for immunophenotyping of patients with clear-cell renal cell carcinoma (Figure 8A). This evidence concerns the gene IFNG and clear cell renal carcinoma.